Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide association study and polygenic risk score analysis of esketamine treatment response.

Scientific reports - 28 Jul 2020

Li Qingqin S, Wajs Ewa, Ochs-Ross Rachel, Singh Jaskaran, Drevets Wayne C

Abstract excerpt

To elucidate the genetic underpinnings of the antidepressant efficacy of S-ketamine (esketamine) nasal spray in major depressive disorder (MDD), we performed a genome-wide association study (GWAS) in cohorts of European ancestry (n = 527). This analysis was followed by a polygenic risk score approach to test for associations between genetic loading for psychiatric conditions, symptom profiles and esketamine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Depressive Disorder, Major

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Genetic Predisposition to Disease

Share to Genome, Human

Share to Genome-Wide Association Study

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 32724131
DOI: 10.1038/s41598-020-69291-6
PMCID: PMC7387452

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association study and polygenic risk score analysis of esketamine treatment response.PMID 32724131Read ↗

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depressionSemantic proximity Read ↗

Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?Semantic proximity Read ↗

Pharmacogenetics of antidepressant response: a polygenic approachSemantic proximity Read ↗

Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies.Semantic proximity Read ↗

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Semantic proximity Read ↗

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read ↗

Methylome-wide association study of antidepressant use in Generation Scotland and the Netherlands Twin Register implicates the innate immune systemSemantic proximity Read ↗

Ketamine’s pharmacogenomic network in human brain contains sub-networks associated with glutamate neurotransmission and with neuroplasticitySemantic proximity Read ↗

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.Semantic proximity Read ↗

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Semantic proximity Read ↗

Addendum: Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways.Semantic proximity Read ↗

Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.